ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

RFA: Long-Term Cancer Survivors

September 12, 1997

NCI-Approved Clinical Trials

May 28, 2004

Feral Mouse Colony Recompetition Given Concept Approval

November 16, 1990

FDA says new tools needed to speed therapeutics development.

March 26, 2004

NCAB Cool On CCOP, Ponders Questions On Distribution, Numbers Of Centers

December 11, 1981

UPCC Wins $26 Million Center Grant From NCI; Massey Center Opens New Outpatient Clinic.

October 20, 2000